Oncology Biomarker Diagnostics

Linking molecular status to breakthroughs in cancer treatment

MolecularMD Develops Notch1 Next Generation Sequencing Test to Support Clinical Development for OncoMed's anti-Notch1 antibody, OMP-52M51

PORTLAND, OR and CAMBRIDGE, Mass. – June 12, 2014 – MolecularMD Corp., a molecular diagnostics company that provides custom companion diagnostic solutions and supporting clinical trial services for targeted cancer therapies, in collaboration with OncoMed Pharmaceuticals, Inc., will present the development and validation of a proprietary Notch1 Next Generation DNA Sequencing (NGS) test at the upcoming 19th European Hematology Association (EHA) Congress. 

At the EHA, MolecularMD and OncoMed will present the validation studies for the proprietary Notch1 NGS assay being developed to identify Notch1 mutation status in patients with certain hematologic malignancies.  Notch1 mutations have been linked to more refractory lymphoid malignancies, such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and others, putting patients at greater risk for poor outcomes and reduced overall survival.  The MolecularMD Notch1 NGS Assay is being developed as a companion diagnostic to identify patients whose cancer may be more likely to benefit from treatment with OncoMed’s anti-Notch1 antibody, OMP-52M51, currently in Phase 1 clinical studies.

Read more...

MolecularMD to Adopt Oncomine Cancer Research Panel with Ion Torrent Next-Generation Sequencing Platform

CARLSBAD, Calif. – June 2, 2014–  MolecularMD will be validating the Oncomine Cancer Research Panel in their CLIA and FDA 21 CFR part 820 compliant diagnostic testing facility to provide comprehensive genomic tumor profiling to support early and late stage clinical development of molecularly targeted cancer therapies. 

This comprehensive multi-biomarker assay allows concurrent analyses of DNA and RNA in one workflow, allowing researchers to simultaneously detect all four classes of tumor-driving alterations: single nucleotide variants, copy number variants, tumor suppressors and gene fusions. As CROs and their pharma partners validate their use of this new tool, the potential exists for patients to be more effectively enrolled into clinical trials and study designs made easier.

Read more...

MolecularMD Receives CLIA Certification for its Second Next Generation Sequencing Laboratory

PORTLAND, OR and CAMBRIDGE, Mass. – April 4, 2014 – MolecularMD Corp., a molecular diagnostics company that provides custom companion diagnostic solutions and supporting clinical trial services for targeted cancer therapies, today announced certification of its Next Generation Sequencing (NGS) clinical laboratory in Cambridge, Massachusetts under the Clinical Laboratory Improvement Amendments (CLIA) of 1988.  The Cambridge lab complements MolecularMD’s Portland, OR CLIA lab and GMP manufacturing facility to provide custom solutions for NGS-based companion diagnostics. The lab was initially established as a development center of excellence for NGS and has now been expanded as a dedicated center for NGS clinical testing under CLIA to support early stage and pivotal clinical studies.

Read more...

MolecularMD Launches NanoString Platform for Multiplexed Digital Evaluation of Gene Expression and Copy Number Variation in Clinical Specimens

Portland, OR, March 5, 2014 -- MolecularMD Corp. today announced that it has launched the NanoString nCounter® Analysis System for multiplex biomarker evaluation in support of oncology clinical drug development.  Several types of gene panels are  offered for clinical trial applications, including custom-designed multiplex analyses of gene expression, gene fusions,  and copy number variation (CNV). As an nCounter Core Lab, MolecularMD has qualified the nCounter System in its Portland CLIA-certified laboratory where it will offer analytically validated pre-built panels and custom assays on the NanoString platform.

Read more...

MolecularMD to Develop Highly Sensitive Companion Diagnostic Test to Support CML Treatment Free Remission Clinical Trial

Portland, OR, February 19, 2014 -- MolecularMD Corp. today announced that it has entered into a collaboration with Novartis Pharmaceuticals Corporation to develop a companion diagnostic test to aid in the identification of Ph+ chronic myelogenous leukemia (CML) patients who have achieved durable minimal residual disease (MRD) with nilotinib (Tasigna®), and to provide molecular monitoring for patients during treatment-free remission.

MolecularMD will validate an in vitro companion diagnostic test (IVD) designed specifically to monitor CML patients during treatment-free remission.  Clinical studies are currently ongoing to evaluate whether patients can maintain MRD after stopping nilotinib therapy, also called treatment-free remission.

Read more...

More Articles...

  1. MolecularMD Announces Presentations at Upcoming American Society of Hematology Annual Meeting
  2. MolecularMD Announces Presentations at Four Upcoming Scientific Conferences
  3. Personal Genome Diagnostics and MolecularMD Collaborate to Provide Advanced Genomic Testing Services to Cancer Drug Developers
  4. MolecularMD Announces Presentations at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  5. Glenn Miller, Ph.D., Joins MolecularMD as Chief Technology Officer and Executive Vice President
  6. MolecularMD Corp. Obtains License to Commercialize Predictive Diagnostic Based on Actionable Biomarker, DDR2, for Uses in Lung Cancer and Targeted Kinase Therapy
  7. MolecularMD Corp. Offers Testing Services for Determining LKB1 Mutation and Expression Status
  8. MolecularMD Announces Launch of Next Generation Sequencing Services for Oncology Drug Development
  9. MolecularMD Corp. Obtains Exclusive License to LKB1 Uses in Non-Small Cell Lung Cancer
  10. MolecularMD and Ventana Medical Systems, Inc. reach Collaborative Research Agreement: Limits of detection and sensitivity for PTEN gene using in-situ hybridization and immunohistochemistry methods
  11. MolecularMD Announces Next Generation Sequencing Presentation at Upcoming American Society of Hematology Annual Meeting
  12. MolecularMD Announces Three Presentations Highlighting Non-Invasive Biomarker Detection and NGS Validation at Upcoming Scientific Conferences
  13. MolecularMD and ARIAD Announce Voluntary Withdrawal Of MolecularMD’s Premarket Approval Application For BCR-ABL T315I Mutation Test
  14. MolecularMD Submits Premarketing Approval Application to the FDA for its BCR-ABL T315I Mutation Test, a Companion Diagnostic to Ponatinib, an investigational BCR-ABL inhibitor
  15. MolecularMD Closes $6 Million Series B Financing And Announces Ensuing Growth Initatives
  16. MolecularMD Announces Issuance Of Patent Covering Methods For Therapeutic Resistance Monitoring In Lung Cancer Patients
  17. Medco Partners with MolecularMD on Personalized Medicine Program for Chronic Myeloid Leukemia
  18. Ariad And MolecularMD Announce Collaboration For A Companion Diagnostic Test For The T315I BCR-ABL Mutation In Patients With CML
  19. MolecularMD Corp. Obtains Exclusive License from NYU and MSKCC for BRAF Melanoma Assay
  20. MolecularMD Establishes New Operations Facility to Support Growth in Personalized Cancer Medicine Business

Oncology Thought Leaders Series:
Brian Druker, MD speaks on the value of
companion diagnostics in patient outcomes